24 – 30 November 2012
Alma Adler speaks to BBC News about man flu and the UK Flusurvey: “We haven’t found any evidence of ‘man flu’ yet. The biggest risk factor is having children under the age of 18 and for this reason women are … Continue reading
Monthly Archives: November 2012
MRC Funding
The MRC have recently agreed to fund a three year project in the lab investigating human serum efficacy determinants in Trypanosoma brucei, specifically looking at intracellular transport and activation of the lytic factor(s). This will employ a similar approach to … Continue reading
17 – 23 November 2012
Alma Adler in the Telegraph for the launch of the UK Flusurvey and the risk of catching flu on your daily commute: “Last year we found no difference in the chance of reporting a flu-like illness in people who took … Continue reading
Why study African trypanosomes?
We’ve always needed to be able to justify our chosen area of research, and this is particularly the case in current times when funding is so hard to come by. This question is also pertinent given the recent successes achieved … Continue reading
10 – 16 November 2012
Martin McKee speaks to Reuters about calls for a global treaty to stop the lethal trade in fake medicines: “We hope that this will form the basis for getting some consensus on a definition of counterfeit drugs, which would then … Continue reading
3 – 9 November 2012
Eleanor Riley speaks to Reuters about the latest results of the RTS,S vaccine study: “We’re all a bit frustrated that it has proven so hard to make a malaria vaccine. The question is how much money are the funders willing … Continue reading
Invited talk at Nottingham University
Thanks to Bill Wickstead for inviting me to give a talk as part of the Nottingham University School of Biology seminar series (17/10/2012). I spoke about High throughput genetic analysis in Trypanosoma brucei – deciphering trypanosome biology; an all encompassing … Continue reading
27 October – 2 November 2012
Kara Hanson in the Irish Journal on research to evaluate the Affordable Medicines Facility for malaria (AMFm): “Tapping into the private sector distribution chain can have a major influence on which antimalarial treatments are available and their price and quality … Continue reading